Contact this trialFirst, we need to learn more about you.
mTOR Inhibitor
Sapanisertib for Non-Small Cell Lung Cancer
Recruiting1 awardPhase 2
Santa Rosa, California
This trial is testing a new drug, sapanisertib, for patients with a specific type of lung cancer that has progressed after two other treatments. Patients are split into two groups based on a gene mutation, with one group having the mutation and the other not. The trial will evaluate how well sapanisertib works on its own in patients with this relapsed or refractory cancer.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.